Liman Andrew D, Liman Agnes K, Shields Jenna, Englert Becky, Shah Rashmikant
Hematology and Oncology, VA Pittsburgh Healthcare System, University of Pittsburgh School of Medicine, Pittsburgh, PA 15240, USA.
Pathology, VA Pittsburgh Healthcare System, University of Pittsburgh School of Medicine, Pittsburgh, PA 15240, USA.
Case Rep Oncol Med. 2016;2016:5982313. doi: 10.1155/2016/5982313. Epub 2016 Aug 17.
Adamantinoma is a rare low-grade malignant bone tumor of epithelial origin. Metastatic adamantinoma has been reported to be resistant to chemotherapy. We report a case of metastatic adamantinoma to the lung, 10 years after the initial diagnosis of tibial mass. The patient received radiation therapy to the lung with partial response. A surveillance PET scan revealed progression of the lung mass and biopsy confirmed to be progressive residual metastatic adamantinoma. He received carboplatin and etoposide for 7 months and achieved a partial response. Four months later, PET scan showed disease progression. We started him on sunitinib, a multikinase inhibitor. He achieved a good partial response for 3 years. He died due to pneumonia at the age of 72.
造釉细胞瘤是一种罕见的起源于上皮的低度恶性骨肿瘤。据报道，转移性造釉细胞瘤对化疗耐药。我们报告一例在最初诊断胫骨肿物10年后发生肺转移的造釉细胞瘤病例。该患者接受了肺部放射治疗，部分缓解。一次监测PET扫描显示肺部肿物进展，活检证实为进行性残留转移性造釉细胞瘤。他接受了7个月的卡铂和依托泊苷治疗，获得部分缓解。4个月后，PET扫描显示疾病进展。我们让他开始使用多激酶抑制剂舒尼替尼治疗。他获得了3年的良好部分缓解。他在72岁时死于肺炎。
